Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

se 3 studies (D9901 and D9902A), Dendreon would expect to achieve the pre-specified criterion for significance and would amend the BLA submission with the FDA based on these interim results.

"The amendment of the SPA allows us to accelerate the expected timing of our final results by a year while maintaining comparable power for the study," said Mitchell H. Gold, president and chief executive officer of Dendreon. "Our commitment to helping patients with prostate cancer is unwavering, and we remain focused on providing the necessary data to the FDA as quickly as possible to enable us to bring PROVENGE to the men in need of a new treatment option."

Conference Call Information

Dendreon will host a conference call tomorrow at 8:00 a.m. PT, 11:00 a.m. ET. To access the live call, dial 1-877-548-7901 (domestic) or +1-719-325-4844 (international). The call will also be audio webcast and will be available from the Company's website at http://www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 5074038. The replay will be available from 7:30 pm ET on Thursday, March 13 until 11:59 pm ET on Saturday, March 15. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.

About IMPACT Study Design

The IMPACT trial is a randomized, double blind, placebo controlled Phase 3 study, which enrolled just over 500 men with metastatic, androgen independent prostate cancer with a primary endpoint of overall survival.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than o
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The Asian Automatic patient billing report ... and forecast of revenue. The Automatic patient billing market ... million by 2018, at a developing CAGR of 7.2% ... of the Asian Automatic patient billing market, to get ... provides a glimpse of the segmentation of this market ...
(Date:10/19/2014)... 2014 The Asian Orthopedic braces and support ... with analysis and forecast of revenue. The Orthopedic braces and ... around $416.5 million by 2018, at a developing CAGR of ... of the Asian Orthopedic braces and support systems market, to ... provides a glimpse of the segmentation of orthopedic braces and ...
(Date:10/18/2014)... (PRWEB) October 19, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers, restraints, challenges, opportunities, current market trends, ... along with the estimates and forecasts of the ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The Asian ... in Asia with analysis and forecast of revenue. The ... to $712.3 million by 2018, at a CAGR of ... TOC of the Asian arthroscopic devices market, to get ... provides a glimpse of the segmentation of arthroscopic devices ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4
... - ... ... PDL BioPharma, Inc.,(PDL) (Nasdaq: PDLI ) today announced a ... of novel antibodies in,oncology and select immunological diseases, following a months-long,business ...
... Aug. 28 The American Chemical Society,(ACS) presented the ... prestigious 2007 Heroes of Chemistry award this week,at the ... new 100,percent renewable ingredient -- the first of its ... Tenn., by the DuPont Tate & Lyle Bio,Products joint ...
... Healthcare unit is now licensed to supply ISBT 128-compliant label,design and ... ... and laboratories, MILWAUKEE, Aug. 28 Niceware(R) International, ... enables,Niceware Healthcare to provide ISBT 128-compliant blood bag labeling,software solutions that ...
Cached Biology Technology:PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 2PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 3PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 4PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 5DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM) 2DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM) 3DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM) 4Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software 2
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
(Date:10/14/2014)... WORCESTER, MA – A team of scientists led ... School (UMMS) and the University of Miami Miller ... likely a key genetic pathway underlying bipolar (manic ... better drugs for treating bipolar affective disorder, as ... , The new findings, published online this week ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... Rochelle, NY, December 21, 2010Pregnancy among women veterans who served ... mental health problems such as depression, anxiety, and post-traumatic stress ... of Women,s Health , a peer-reviewed journal published by Mary ... The stress associated with military service in a ...
... Cold Spring Harbor, NY-- Newly published research led by ... Laboratory (CSHL) sheds important new light on how neurons ... This activity, called synapse validation, is at the heart ... is directly implicated in pathology that gives rise to ...
... Nutritional supplementation with Spirulina, a nutrient-rich, blue-green algae, ... neurons in a mouse model of amyotrophic lateral ... University of South Florida neuroscientists have found. ... a spirulina-supplemented diet may provide clinical benefits for ...
Cached Biology News:CSHL scientists show in unprecedented detail how cortical nerve cells form synapses with neighbors 2CSHL scientists show in unprecedented detail how cortical nerve cells form synapses with neighbors 3Blue-green algae tested for treating ALS 2
... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide White ... CHAPS and CHAPSO. Has reduced electrostatic interactions ... chromatography on DEAE-cellulose. Aggregation number: 8-16. ... H 2 O. Aggregation number 8 - ...
... N-Dodecyl-N,N-(dimethylammonio)butyrate White crystalline ... similar to DDMAU (Cat. No. 252005) but ... arm. More efficient for the extraction of ... DDMAU. Purity: ≥98% by TLC. ...
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Biology Products: